| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f65418655c62cdfeecde1ce087e8acbb |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4965 |
| filingDate |
2009-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_178cf98fe31f98c945c8e1673ebc79d2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_322e48d617ed864988351342a014db23 |
| publicationDate |
2015-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2009255333-B2 |
| titleOfInvention |
Treatment for neurological and mental disorders |
| abstract |
Methods for treating neurological or mental disorders in humans and the symptoms associated therewith are provided by administering eltoprazine and/or related compounds. In some embodiments, specific symptoms are treated by administering eltoprazine and/or a related compound in an effective amount to ameliorate the symptoms. Of particular significance are symptoms that are associated with cognitive dysfunction where eltoprazine will improve the symptoms and the disorder associated with that symptom. Of particular interest are non-ADHD-associated inattention, hyperactivity and impulsiveness. The methods provided herein are especially useful for improving functional recovery after CNS injury such as stroke where improved cognitive function will facilitate the acquisition of learning and memory of rehabilitative tasks. |
| priorityDate |
2008-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |